HACKENSACK, N.J., Nov. 21, 2025 /PRNewswire/ — Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated Lombardi Comprehensive Cancer ...
Disc Medicine has launched a small clinical trial to test DISC-3405, its treatment candidate for reducing iron levels and easing iron overload, in people with sickle cell disease (SCD). The Phase 1b ...
CHICAGO — The Persian Gulf nation of Oman, located at the crossroads of Africa and Asia, presents a diverse ecosystem of patients with sickle cell disease (SCD), including a unique genotype specific ...
LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...
The first sickle cell disease (SCD) patient has been enrolled in a Phase 1b clinical trial evaluating iadademstat, Oryzon Genomics‘ investigational oral therapy designed to boost fetal hemoglobin (HbF ...
Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCD Iadademstat has demonstrated a favorable ...
Background: Late gadolinium enhancement (LGE) is an established predictor of sudden cardiac death (SCD) in nonischemic dilated cardiomyopathy (DCM). However, the prognostic value of LGE ...
Background: Hypertrophic cardiomyopathy (HCM) is a common cause of sudden cardiac death (SCD) in young people, sometimes accompanied by malignant ventricular arrhythmias. Recent advances in artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback